ADVANCES IN PHARMACEUTICAL BIOTECHNOLOGY FOR CANCER TREATMENT: THE CONTRIBUTION OF MONOCLONAL ANTIBODIES AND GENE THERAPY
| dc.contributor.advisor | Zsebik, Barbara | |
| dc.contributor.advisordept | Gyógyszerésztudományi Kar::Biofarmácia Tanszék | |
| dc.contributor.author | Nguyen, Ngoc Thuy Anh | |
| dc.contributor.department | DE--Gyógyszerésztudományi Kar | |
| dc.contributor.opponent | Fenyvesi, Ferenc | |
| dc.contributor.opponent | Korpos, Éva | |
| dc.contributor.opponentdept | Gyógyszerésztudományi Kar | |
| dc.contributor.opponentdept | Gyógyszerésztudományi Kar | |
| dc.date.accessioned | 2026-04-22T10:49:22Z | |
| dc.date.available | 2026-04-22T10:49:22Z | |
| dc.date.created | 2026-04-02 | |
| dc.description.abstract | This thesis provides a comprehensive review of the role of pharmaceutical biotechnology in advancing cancer treatment, with a focus on precision oncology. It examines two principal therapeutic strategies: monoclonal antibodies, which enable targeted recognition of tumor-associated antigens, and gene-based therapies designed to enhance anti-tumor immune responses. Particular emphasis is placed on chimeric antigen receptor T-cell (CAR-T) therapy, including its clinical success in hematological malignancies and ongoing research aimed at its application in solid tumors, as well as tumor-infiltrating lymphocyte (TIL) therapy. In addition, the thesis highlights the increasing importance of nanotechnology and nanoparticle-based delivery systems in improving therapeutic specificity and stability. Despite current limitations, such as high production costs and challenges in tumor penetration, these approaches demonstrate considerable potential. Overall, the findings underscore the transformative impact of biotechnological innovations in the development of personalized cancer therapies. | |
| dc.description.course | gyógyszerész | |
| dc.description.courselang | angol | |
| dc.description.degree | egységes, osztatlan | |
| dc.format.extent | 49 | |
| dc.identifier.uri | https://hdl.handle.net/2437/406421 | |
| dc.language.iso | en | |
| dc.rights.info | Hozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében. | |
| dc.subject | Gene therapy | |
| dc.subject | CAR-T cell therapy | |
| dc.subject | Monoclonal antibodies | |
| dc.subject | Targeted therapy | |
| dc.subject | Cancer immunotherapy | |
| dc.subject | Precision oncology | |
| dc.subject | Nanoparticles | |
| dc.subject.dspace | Biology::Biotechnology | |
| dc.subject.dspace | Medicine::Oncology | |
| dc.title | ADVANCES IN PHARMACEUTICAL BIOTECHNOLOGY FOR CANCER TREATMENT: THE CONTRIBUTION OF MONOCLONAL ANTIBODIES AND GENE THERAPY |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 2 (Összesen 2)
Nincs kép
- Név:
- Thesis_Nguyenngocthuyanh.pdf
- Méret:
- 870.68 KB
- Formátum:
- Adobe Portable Document Format
- Leírás:
Nincs kép
- Név:
- DECLARATION.pdf
- Méret:
- 3.67 MB
- Formátum:
- Adobe Portable Document Format
- Leírás:
Engedélyek köteg
1 - 1 (Összesen 1)
Nincs kép
- Név:
- license.txt
- Méret:
- 1.94 KB
- Formátum:
- Item-specific license agreed upon to submission
- Leírás: